ADVANCED MELANOMA

This study is for people with advanced melanoma that has continued to grow despite receiving two standard types of immunotherapy. It aims to see if a new treatment—a modified virus injected directly into tumors, combined with the drug nivolumab—works better and helps people live …

This study is testing whether combining three immunotherapy drugs—fianlimab, cemiplimab, and ipilimumab—is safe and effective for people with advanced melanoma that has continued to grow despite previous immunotherapy treatment. The trial will enroll 88 adults whose melanoma has …

This study is testing whether giving immunotherapy drugs before surgery can lead to better outcomes for people with advanced melanoma that has spread to nearby lymph nodes or tissue. The treatment aims to help the patient's own immune system attack the cancer to shrink tumors pri…

This early-stage study is testing the safety of a new combination treatment for people with advanced melanoma that has continued to grow despite standard immunotherapy. The treatment involves infusing specially prepared 'memory-like' natural killer (NK) immune cells, either from …

This study is testing whether adding high-intensity exercise and a high-fiber diet to standard immunotherapy can improve health outcomes for people with advanced melanoma. Researchers want to see if these lifestyle changes are doable during treatment and if they can improve gut h…

This is the first study in humans testing a new drug called AB821 for people with advanced melanoma and other solid tumors that have spread. The main goal is to find a safe dose and understand how the drug works in the body. Researchers will also check if the drug helps shrink tu…

This study is testing whether giving standard cancer treatments at home is as safe and effective as giving them in a clinic. It aims to see if receiving care at home reduces stress, improves quality of life, and is preferred by patients with advanced cancers. About 220 participan…

This early-stage study is testing a new drug called T3011 in people with advanced melanoma, a serious form of skin cancer. The main goals are to see if the treatment is safe and tolerable, and to get an early look at whether it can shrink tumors. The study will enroll about 42 pa…

This early-stage study tests whether a personalized immune cell therapy can help control advanced melanoma. Doctors take immune cells from a patient's own tumor, grow large numbers of them in a lab, then infuse them back into the patient after mild chemotherapy. The study aims to…

This study is testing a new personalized treatment for advanced melanoma, a serious skin cancer. It involves taking a patient's own immune cells from their tumor, growing large numbers of them in a lab, and then infusing them back into the patient to fight the cancer. The trial i…

This is a first-in-human study to find a safe dose of a new oral drug called IACS-6274. It will be tested alone and in two different drug combinations in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the safety …

This early study is testing whether combining two experimental treatments can help control advanced melanoma. Eleven patients receiving immunotherapy before surgery will get focused ultrasound to heat and destroy tumor tissue, followed by an injection of an immune-stimulating dru…

This study is testing if adding an experimental drug called EIK1001 to the standard first treatment (pembrolizumab) works better for controlling advanced melanoma. About 740 adults with newly diagnosed, advanced melanoma will receive either the new combination or the standard tre…

This early-stage study is checking if it's safe to add two common, low-cost drugs—naltrexone and propranolol—to standard immunotherapy for advanced melanoma. The idea is that these drugs, which block the body's stress response, might help the immune system fight cancer better. Re…

This study is testing whether a new drug called tebentafusp, given alone or with pembrolizumab, works better than standard care options for people with advanced melanoma that has worsened despite previous treatments. The trial will enroll 540 participants with specific genetic ma…

This Phase 3 trial is testing whether adding a new drug called brenetafusp (IMC-F106C) to the standard immunotherapy nivolumab works better than current treatments for advanced melanoma. It will enroll about 680 people with previously untreated, advanced melanoma who have a speci…

This study is testing new drug LBL-024, both alone and in combination with other medications, for people with advanced melanoma that has spread. Researchers want to see if these treatments can help control the cancer and are safe for patients. The trial will enroll about 200 adul…